About: Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients
Creator	Shurin, Michael Wheeler, Sarah Kattel, Gaurav Keetch, Christian Mcbreen, Jeffrey Mitchell, Gretchen Shurin, Galina
Source	Elsevier; Medline; PMC
abstract	Objectives Humoral immune response to SARS-CoV-2 infection has been reported in several patient cohorts with results that vary by method and population studied due to the lack of reliable commercial assays available as the pandemic initially spread. We sought to clinically assess commercial prototype SARS-CoV-2 IgG and IgA assays for use in screening for prior infection and convalescent plasma donation. Design and Methods Prototype SARS-CoV-2 IgG and IgA assays from Euroimmun were assessed utilizing remnant specimens. Specificity testing used specimens in their convalescent window for the common coronaviruses and other infectious diseases known to be associated with increased non-specificity in serologic assays. Sensitivity testing utilized serial specimens from molecularly confirmed SARS-CoV-2 critically ill patients to assess seroconversion. Utilizing recombinant spike protein we also developed a competitive confirmation procedure to increase assay specificity. Results We determined specificity to be 97% and 81%, respectively, when indeterminate samples were considered positive and 99% and 86% when indeterminate samples were considered negative. We developed a new confirmation methodology to enhance the specificity of the assays with an anticipated specificity of 98% for IgA. Valuation of hospitalized COVID-19 patients determined median IgA seroconversion to be 8 days and IgG 10 days. Neither level nor timing of antibody response correlated with days on ventilation. End titer measurements indicate that validated improved assays may be capable of semi-quantitative measurement. Conclusions We found these assays to be clinically acceptable for the high prevalence population tested, for instance, for convalescent plasma donation.
has issue date	2020-08-26(xsd:dateTime)
bibo:doi	10.1016/j.clinbiochem.2020.08.008
bibo:pmid	32858060
has license	els-covid
sha1sum (hex)	5f2786af86c014c68ea54160a4641cb362170085
schema:url	https://doi.org/10.1016/j.clinbiochem.2020.08.008
resource representing a document's title	Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients
has PubMed Central identifier	PMC7448777
has PubMed identifier	32858060
schema:publication	Clin Biochem
resource representing a document's body	covid:5f2786af86c014c68ea54160a4641cb362170085#body_text
is schema:about of	named entity 'Journal' named entity 'reliable' named entity 'Evaluation' named entity 'Evaluation' named entity 'patient cohorts' named entity 'SARS-CoV-2' named entity 'serologic test' named entity 'SARS-CoV-2' named entity 'prototype' named entity 'prototype' named entity 'IgA' named entity 'serologic test' named entity 'pandemic' named entity 'PANDEMIC' named entity 'PROTOTYPE' named entity 'METHOD' named entity 'REPORTED' named entity 'DONATION' named entity 'SCREENING' named entity 'RELIABLE' named entity 'INITIALLY' named entity 'LACK' named entity 'POPULATION' named entity 'convalescent plasma' named entity 'SARS-CoV-2' named entity 'infection' named entity 'Humoral immune response' named entity 'SARS-CoV-2' covid:arg/5f2786af86c014c68ea54160a4641cb362170085 named entity 'CONVALESCENT PLASMA' named entity 'HUMORAL IMMUNE RESPONSE' named entity 'infection' named entity 'IgG' named entity 'COMMERCIAL' named entity 'JOURNAL ' named entity 'SARS-CoV-2' named entity 'population' named entity 'patient cohorts' named entity 'IgG' named entity 'infection' named entity 'prototype' named entity 'prior' named entity 'IgA' named entity 'SARS-CoV-2' named entity 'assess' named entity 'convalescent' named entity 'studied' named entity 'patients' named entity 'serologic' named entity 'patients' named entity 'infection' named entity 'plasma donation' named entity 'initially' named entity 'serologic' named entity 'screening' named entity 'Objectives' named entity 'immune response' named entity 'SARS-CoV-2' named entity 'RESPONSE TO' named entity 'INFECTION' named entity 'COHORTS' named entity 'prototype' named entity 'SPREAD' named entity 'AVAILABLE' named entity 'IGG' named entity 'SARS-CoV-2' named entity 'prototype' named entity 'SARS-COV-2' named entity 'USE' named entity 'DUE TO' named entity 'PATIENT' named entity 'RESULTS' named entity 'SARS-COV-2 INFECTION' named entity 'OBJECTIVES' named entity 'PRIOR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software